154 related articles for article (PubMed ID: 32897759)
1. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
Rowin EJ; Burrows A; Madias C; Estes NAM; Link MS; Maron MS; Maron BJ
Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008123. PubMed ID: 32897759
[TBL] [Abstract][Full Text] [Related]
2. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
6. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
9. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
[TBL] [Abstract][Full Text] [Related]
10. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
11. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
15. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG
Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750
[TBL] [Abstract][Full Text] [Related]
16. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
Lambiase PD; Gold MR; Hood M; Boersma L; Theuns DAMJ; Burke MC; Weiss R; Russo AM; Kääb S; Knight BP
Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
[TBL] [Abstract][Full Text] [Related]
18. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
Dichtl W; Wolber T; Paoli U; Brüllmann S; Stühlinger M; Berger T; Spuller K; Strasak A; Pachinger O; Haegeli LM; Duru F; Hintringer F
Clin Cardiol; 2011 Jul; 34(7):433-6. PubMed ID: 21678454
[TBL] [Abstract][Full Text] [Related]
19. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.
Schinkel AF; Vriesendorp PA; Sijbrands EJ; Jordaens LJ; ten Cate FJ; Michels M
Circ Heart Fail; 2012 Sep; 5(5):552-9. PubMed ID: 22821634
[TBL] [Abstract][Full Text] [Related]
20. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
